GERN MEXC RealStocks
Own real GERN shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 02:28:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Geron Corp. (GERN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.00, with a market capitalization of $606.81M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.84 to $2.01. This page covers its latest market performance, valuation, price trends and company information.
$606.81M | |
$1.00 | |
$1.01 | |
$0.95 | |
$1.00 | |
32.88M | |
12.34M | |
-- | |
$2.01 | |
$0.84 | |
-- | |
2026-09-30 |
Geron Corp. (GERN) last closed at $1.00 as of 2026-11-19 00:31:00, down 0.04% ($0.00) from the previous close of $1.00.
During the latest regular trading session, GERN traded between $0.95 and $1.02, with a volume of 32.88M shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Geron Corp. (GERN) moved from $1.00 to $1.00, representing a gain of 0.05% ($0.00).
The stock traded between $0.94 and $1.03 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 9.26 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 13.4%
GERN is currently trading at $1.00, placing it 13.4% of the way from its 52-week low of $0.84 to its 52-week high of $2.01. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 258 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Geron Corp. (GERN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to GERN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between GERN shares and USD.
GERN Shares to USD
1.00 GERN shares = 0.997 USD
Calculations are estimates based on the latest available price and are for reference only.